Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 53Neoplasm Metastasis 16Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Brain Neoplasms 5Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Melanoma 3Glioma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Breast Diseases 3Sarcoma, Ewing 2Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma 2Glioblastoma 2Advanced Cancer 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Temozolomide 3perillyl alcohol 1olutasidenib 1abemaciclib 1Transplantation, Homologous 1Transplantation, Autologous 1RRx-001 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Spinal Cord Neoplasms × abemaciclib × Clear all
NCT06413706 2026-05-22

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

Eli Lilly and Company

Phase 2 Active not recruiting
45 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡